Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...

Chicago Partners Investment Group LLC bought a new stake in shares of Novartis AG (NYSE:NVS – Free Report) during the 4th ...

DAVENPORT & Co LLC reduced its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 3.3% in the fourth quarter, ...

Novartis had already given up developing iscalimab for liver transplant patients in 2022 after a phase 2 trial found the drug had a “less favorable risk-benefit profile” than tacrolimus ...

Novartis has declared that they don’t see space for providing a differentiated therapeutic profile in obesity ... of income at a critical moment. The company’s cash position is nearly double ...